ANIK Anika Therapeutics Inc.

Anika Announces Third Quarter 2024 Results Conference Call Date

Anika Announces Third Quarter 2024 Results Conference Call Date

BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 financial results before the opening of the market on Thursday, October 31, 2024, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.

The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 31842. A live audio webcast and accompanying presentation materials will be available in the section of Anika's website, . The call will be archived and accessible on the same website shortly after its conclusion.

About Anika

(NASDAQ: ANIK) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit

ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc.

For Investor Inquiries:

Anika Therapeutics, Inc.

Matt Hall, 781-457-9554

Director, Corporate Development and Investor Relations



EN
17/10/2024

Underlying

ANIKAnika Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anika Therapeutics Inc.

 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika To Participate in December 2024 Investor Conferences

Anika To Participate in December 2024 Investor Conferences BEDFORD, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that senior management will participate in the following upcoming conferences. 36th Annual Piper Sandler Healthcare Conference in New York, NY on December 3rd. Dr. Cheryl Blanchard, President and CEO of Anika and Steve Griffin, Executive Vice President and Chief Financial Officer, are scheduled to present at 10:30am ET. Management will also participate in one-on-one investor mee...

November 22, 2024 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Third Quarter 2024 Financial Results

Anika Reports Third Quarter 2024 Financial Results Updating 2024 fiscal year guidance to reflect announced changes to business strategy, including the sale of Arthrosurface and planned divestiture of Parcus Medical, and U.S. OA Pain Management headwinds Strategy to focus on market leading OA Pain Management and high-growth Regenerative Solutions Company to categorize revenue into OEM Channel and Commercial Channel; Commercial Channel remains on track to achieve ~17% CAGR since 2021 with recent performance fueled by the IntegrityTM Implant System, which grew 40%+ sequentially in the third ...

October 31, 2024 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Announces Strategic Update of Business with Sale of Arthrosurfac...

Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical Company to Focus on Profitable Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio, Streamline Operations and Enhance Growth Profile BEDFORD, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced the divestiture of its Arthrosurface business and the intention to divest of the Parcus Medical business. These decisions are the result of the Company’s...

October 31, 2024 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Announces Third Quarter 2024 Results Conference Call Date

Anika Announces Third Quarter 2024 Results Conference Call Date BEDFORD, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2024 financial results before the opening of the market on Thursday, October 31, 2024, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID num...

October 17, 2024 1 EN
 PRESS RELEASE
Free
ANIK Anika Therapeut...

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on October 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 6,350 shares of common stock at a per share exercise price of $24.27, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the ...

October 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch